Article

Urologists' interests at heart in patients' rights bill

On Thursday, August 2, 2001, the House of Representatives finally passed its version of the "Patients' Bill of Rights"-one that contains a cap on monetary awards to patients found to have been injured by an HMO's actions. First, I would like to reiterate that the AUA's top priority is a patient protection bill that will work and be signed by the president. AUA has been working to this end for the past 6 years, since joining the Patient Access Coalition. I can assure you that all of the recent bills-conservative and liberal-now contain the following principles long advocated by AUA:

Related Videos
Amy E. Krambeck, MD, answers a question during a Zoom video interview
Alicia Morgans, MD, MPH, answers a question during a Zoom video interview
2 experts in this video
2 experts in this video
Related Content
Conceptual image for prostate cancer treatment | Image Credit: © Dr_Microbe - stock.adobe.com
February 21st 2025

Piflufolastat F 18 yields high detection rate even at low PSA levels for prostate cancer

Benjamin P. Saylor
Total detection rate was 36% (13/36) in the ultra-low PSA group and 51% (47/93) in the low-PSA group.
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
February 11th 2025

Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management

Max Kates, MD Neal Shore, MD, FACS Katie S. Murray, DO, MS
Panelists discuss the impact of long-term care in patients with non–muscle-invasive bladder cancer (NMIBC), considering the unique needs of specific patient groups and highlighting advancements in NMIBC treatment that may support better care experiences for patients.
Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
February 20th 2025

Final CheckMate 9ER data show long-term efficacy of nivolumab/cabozantinib in RCC

Benjamin P. Saylor
Robert J. Motzer, MD, reported that median PFS was 16.4 months in the nivolumab plus cabozantinib arm (95% CI, 12.5-19.3) vs 8.3 months in the sunitinib arm (95% CI, 7.0-9.7) (HR=0.58, 95% CI, 0.49-0.70).
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
January 29th 2025

Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC

Max Kates, MD Neal Shore, MD, FACS Tom Jayram, MD
Panelists explore challenges in identification of intermediate risk patients and emphasize importance of risk stratification to improve outcomes in regards to NMIBC.
CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC
February 20th 2025

CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

Thomas E. Hutson, DO, PharmD
"The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
Two doctors being discussing patient history | Image Credit: © Freedomz - stock.adobe.com
February 19th 2025

Level of service for vasectomy prompts coding confusion

Jonathan Rubenstein, MD Mark Painter
"With the requirements for an E/M code as noted above, we agree with you that the supporting documentation, if appropriately documented, would support a level 3 outpatient visit for a visit regarding counseling for contraception or family planning," write Jonathan Rubenstein, MD, and Mark Painter.
© 2025 MJH Life Sciences

All rights reserved.